Nuscale Power earnings missed by $0.02, revenue fell short of estimates
In a recent transaction, Sue Gail Eckhardt, a director at Exelixis, Inc. (NASDAQ:EXEL), sold a total of 11,568 shares of the company’s common stock, generating proceeds of $405,111. The shares were sold on February 14, 2025, at prices ranging from $35.01 to $35.04 per share. The transaction occurs as Exelixis trades near its 52-week high, with the stock delivering an impressive 70% return over the past year. According to InvestingPro analysis, the company appears slightly undervalued at current levels.
Prior to the sale, Eckhardt exercised options to acquire 7,712 shares at a price of $23.24 per share, with the total value of these transactions amounting to $179,226. Following these transactions, Eckhardt now directly owns 30,406 shares of Exelixis common stock. InvestingPro data reveals the company maintains excellent financial health with a perfect Piotroski Score of 9, while management has been actively buying back shares.
These transactions were conducted under a pre-established trading plan, allowing for the systematic sale of shares over time. For deeper insights into Exelixis’s financial health and valuation metrics, access the comprehensive Pro Research Report available exclusively on InvestingPro, along with 13 additional ProTips for informed investment decisions.
In other recent news, Exelixis has been the focus of several analyst updates and company developments. JMP Securities maintained a Market Outperform rating with a $41 price target, highlighting Exelixis’s fourth quarter 2024 revenue, which met market expectations. The firm emphasized the potential of the investigational drug zanzalintinib, which Exelixis considers a significant opportunity. Truist Securities also raised its price target for Exelixis to $43, citing optimism from positive data in the Phase 1 STELLAR-001 study, boosting confidence in the ongoing Phase 3 STELLAR-303 trial for colorectal cancer.
Stifel, however, maintained a Hold rating and increased the price target to $36, noting the anticipated completion of Exelixis’s share repurchase program and adjustments in success estimates for zanzalintinib in certain cancers. The firm also referenced data from the STELLAR-001 expansion cohort presented at a recent meeting, which did not change their outlook on the STELLAR-303 trial. Despite the positive developments, Stifel remains cautious, reflecting a view that the stock may not outperform the market.
These updates indicate a mixed but generally optimistic sentiment among analysts regarding Exelixis’s future prospects, particularly concerning its drug development pipeline and strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.